Skip to main content
Fig. 3 | Journal of Nanobiotechnology

Fig. 3

From: Neutrophil-mediated clinical nanodrug for treatment of residual tumor after focused ultrasound ablation

Fig. 3

Inflammation-mediated targeting delivery. a Schematic illustration of the mechanism of PLD release from PLD@NEs (left). Fluorescence images of NETs released from PLD@NEs after incubation with PMA (100 nM) (upper right) for 4 h in comparison with fMLP (100 nM) (lower right). b Fluorescence image of Hepa1-6 cells after incubation with supernatant medium of untreated/PMA (100 nM)-treated PLD@NEs for 8 h. The nuclei were stained with DAPI. Scale bar: 50 μm. c, d Cytotoxicity of PMA-treated PLD@NEs against Hepa1-6 cells after incubation for 24 h (c) or 48 h (d). The data are shown as the mean ± SD. n = 5; *p < 0.05, ** p<0.01, *** p<0.001. e Tumor permeability of PLD@NEs after incubation with 3D Hepa1-6 tumor spheroids for 8 h. CLSM images were obtained from the surface to the middle of the tumor spheroid with a Z-stack thickness of 50 μm. Scale bar: 200 μm

Back to article page